Australia markets closed

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
30.64+2.16 (+7.58%)
At close: 04:00PM EDT
31.16 +0.52 (+1.70%)
After hours: 04:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 780.74M
Enterprise value 479.63M
Trailing P/E 478.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.65
Price/book (mrq)1.96
Enterprise value/revenue 4.89
Enterprise value/EBITDA -8.74

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-51.59%
S&P500 52-week change 3-7.20%
52-week high 378.58
52-week low 315.58
50-day moving average 323.73
200-day moving average 335.57

Share statistics

Avg vol (3-month) 3319.56k
Avg vol (10-day) 3240.48k
Shares outstanding 526.26M
Implied shares outstanding 6N/A
Float 824.83M
% held by insiders 14.92%
% held by institutions 180.75%
Shares short (14 July 2022) 41.31M
Short ratio (14 July 2022) 43.33
Short % of float (14 July 2022) 45.97%
Short % of shares outstanding (14 July 2022) 44.98%
Shares short (prior month 14 June 2022) 41.31M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin -40.37%
Operating margin (ttm)-66.52%

Management effectiveness

Return on assets (ttm)-10.25%
Return on equity (ttm)-10.62%

Income statement

Revenue (ttm)110.2M
Revenue per share (ttm)4.32
Quarterly revenue growth (yoy)53.10%
Gross profit (ttm)78.26M
EBITDA -67.95M
Net income avi to common (ttm)-44.49M
Diluted EPS (ttm)-2.04
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)273.17M
Total cash per share (mrq)10.39
Total debt (mrq)7.69M
Total debt/equity (mrq)1.82
Current ratio (mrq)11.08
Book value per share (mrq)16.04

Cash flow statement

Operating cash flow (ttm)-39.34M
Levered free cash flow (ttm)-21.13M